Guido Marcucci
Overview
Explore the profile of Guido Marcucci including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
481
Citations
22775
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Samuels D, Yao J, Samara Y, Yang D, Mokhtari S, Tiemann K, et al.
Front Immunol
. 2025 Mar;
16:1543099.
PMID: 40051639
Introduction: Hemorrhagic cystitis (HC) is an early complication after hematopoietic cell transplant (HCT) with post-transplant cyclophosphamide (PTCy). Hyperhydration can reduce HC, but may lead to fluid overload (FO), which has...
2.
Koller P, Othman T, Yang D, Mokhtari S, Samara Y, Blackmon A, et al.
Bone Marrow Transplant
. 2025 Feb;
PMID: 40016513
Fludarabine and melphalan (FM) conditioning offers effective disease control with an acceptable toxicity profile. Post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis has improved transplant outcomes. We retrospectively reviewed patients...
3.
Wei W, Valerio M, Ma N, Kang H, Truong Nguyen L, Marcucci G, et al.
Biochemistry
. 2025 Feb;
PMID: 39999282
Ran is a small GTPase of the Ras superfamily that governs nucleocytoplasmic transport, including that of miR-126, a microRNA that supports the homeostasis and expansion of leukemia stem cells (LSCs)....
4.
Kang H, Hoang D, Valerio M, Pathak K, Graff W, LeVee A, et al.
J Hematol Oncol
. 2025 Feb;
18(1):16.
PMID: 39920848
Natural products have long been a viable source of therapeutic agents, providing unique structures and mechanisms that may be beneficial for cancer treatment. Herein we first report on the anticancer...
5.
Kang H, Zhang L, Kaadige M, Valerio M, Hoang D, Thode T, et al.
Blood Adv
. 2025 Feb;
PMID: 39908477
No abstract available.
6.
Chen F, Zhao D, Xu Y, Zhang Y, Chen M, Pathak K, et al.
Nat Commun
. 2025 Feb;
16(1):1253.
PMID: 39893171
We reported that an acquired miR-142 deficit transforms chronic phase (CP) chronic myeloid leukemia (CML) leukemic stem cells (LSCs) into blast crisis (BC) LSCs. Given the role of miR-142 in...
7.
Fei F, Telatar M, Tomasian V, Chang L, Gust M, Yew H, et al.
Int J Mol Sci
. 2025 Jan;
26(2).
PMID: 39859151
Recurrent fusions drive the pathogenesis of many hematological malignancies. Compared to routine cytogenetic/fluorescence in situ hybridization (FISH) studies, the RNA-based next-generation sequencing (NGS) fusion assay enables the identification of both...
8.
Ma R, Li Z, Tang H, Wu X, Tian L, Shah Z, et al.
Nat Commun
. 2025 Jan;
16(1):989.
PMID: 39856052
NKp46 is a critical regulator of natural killer (NK) cell immunity, but its function in non-NK innate immune cells remains unclear. Here, we show that NKp46 is indispensable for expressing...
9.
Dona A, Tandoh T, Nigam L, Singer M, Caserta E, Murtadha M, et al.
J Hematol Oncol
. 2025 Jan;
18(1):1.
PMID: 39828738
Background: Reovirus (RV) is an oncolytic virus with natural tropism for cancer cells. We previously showed that RV administration in multiple myeloma (MM) patients was safe, but disease control associated...
10.
Aldoss I, Li S, Zhang J, Clark M, Agrawal V, Pourhassan H, et al.
Blood Adv
. 2025 Jan;
PMID: 39820649
Despite the success of the CD19xCD3 T cell engager blinatumomab in B-cell acute lymphoblastic leukemia (B-ALL), treatment failure is common and can manifest with antigen loss and extramedullary disease (EMD)...